Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01159574 · ClinicalTrials.gov registry record · Phase 2
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT01159574 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 121 participants.
The verdict
NCT01159574, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
This study is intended to investigate the combination of the combination of dexamethasone (Decadron®), Clarithromycin (Biaxin®), and pomalidomide (CC-4047®) \[ClaPd\] in multiple myeloma patients who have relapsed or refractory disease who have failed prior treatment with lenalidomide when used alone or in combination with corticosteroids. Primary endpoint will be response rate to treatment. Secondary endpoints will include toxicity of the combination, time to maximum response, and time to disease progression
Interventions
- DRUG Pomalidomide
- DRUG dexamethasone
- DRUG clarithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2010-08 |
| Est. Completion | 2015-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01159574
The ClinicalTrials.gov registry entry for NCT01159574 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pomalidomide is the first listed.
NCT01159574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01159574 about?
NCT01159574 is a clinical study titled "Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma". This study is intended to investigate the combination of the combination of dexamethasone (Decadron®), Clarithromycin (Biaxin®), and pomalidomide (CC-4047®) \[ClaPd\] in multiple myeloma patients who have relapsed or refractory disease who have failed prior treatment with lenalidomide when used alon...
What is the current status of trial NCT01159574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2010-08. Estimated completion is 2015-05-05.
What interventions are being tested in trial NCT01159574?
The interventions under investigation include: Pomalidomide (DRUG), dexamethasone (DRUG), clarithromycin (DRUG).
Who is sponsoring clinical trial NCT01159574?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.